Hemophilia A Clinical Trial
Official title:
UK-PK Study: National Study of the Implementation of a Pharmacokinetic-Focused Educational Package for Patients Living With Severe Haemophilia A
Prospective, interventional study of pharmacokinetic (PK)-focused FVIII dosing discussions
delivered as part of a patient education package.
The study will capture severe haemophilia A patient reported outcome measures before and
after PK-focused dosing discussions, including a standardised patient education package, that
include personalised PK-guided dosing suggestions from a computational predictive device
(myPKFiT®). The pragmatic study design recognises the CE marked myPKFiT® device is being
implemented into routine care nationally and consequently only requires a single additional
clinic visit for the purpose of consenting.
There is a paucity of patient reported outcome data documenting the impact of PK focused
prophylaxis discussions. This prospective, multicentre UK-PK trial will coincide with the
initiation of the myPKFiT® device in the context of an enhanced clinical review. This will
include a standardised patient education package using a short animated film explaining PK
and personalised prophylaxis, followed by modelling of the patient's own PK using the
myPKFiT® device and discussing the dosing options with the patient. The aim of the PK
educational package is to educate and engage patients and ensure that their treatment
regimens meet their individual needs. In addition, the study will capture the prophylaxis
dosing strategy agreed upon by patients and the clinical team where treatment decisions are
made jointly between patients and the clinical team (concordance). Looking forward,
haemophilia clinical care team members need a marker to judge or predict patient engagement
with this personalising medicine process. Successful consultation strategies may differ if
the team can anticipate how an individual person with haemophilia (PWH) might respond to
discussions about potential change. The primary outcome measure is the Patient Activation
Measure (PAM) which gauges the knowledge, skills and confidence essential to managing one's
own health and healthcare. A PAM score can predict healthcare outcomes including medication
adherence, healthcare utilisation and hospital visits. It is hypothesized that a more
activated patient will be more receptive to changes in their treatment regimen, education and
information about their health condition.
In addition to patient activation, the study will assess a range of patient reported outcomes
and psychological factors using validated tools. These will include patients'
Haemophilia-related quality of life (HAEMO-QoL-A), beliefs about medicines (BMQ),
self-reported adherence (VERITAS-Pro) and activity levels. These tools will provide clear
patient reported outcomes for the haemophilia community, with accompanying EQ5D data,
enabling robust health economic evaluation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03834727 -
Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
|
||
| Completed |
NCT03191799 -
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
|
Phase 3 | |
| Completed |
NCT01599819 -
BAX 855 Dose-Escalation Safety Study
|
Phase 1 | |
| Terminated |
NCT04541628 -
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A
|
Phase 1/Phase 2 | |
| Completed |
NCT02847637 -
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
|
Phase 3 | |
| Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
| Completed |
NCT04085458 -
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
|
Phase 4 | |
| Completed |
NCT04565236 -
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
|
Phase 4 | |
| Recruiting |
NCT05987449 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04621916 -
Preventing Inhibitor Recurrence Indefinitely
|
Phase 4 | |
| Not yet recruiting |
NCT02888223 -
Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
|
Phase 1 | |
| Completed |
NCT02225483 -
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
|
N/A | |
| Completed |
NCT02199717 -
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
|
N/A | |
| Completed |
NCT01217255 -
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
|
||
| Completed |
NCT00969319 -
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
|
N/A | |
| Terminated |
NCT00995046 -
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
|
N/A | |
| Completed |
NCT00868530 -
Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
|
Phase 3 | |
| Completed |
NCT00839202 -
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
|
N/A | |
| Completed |
NCT00629837 -
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
|
Phase 1 | |
| Completed |
NCT02093741 -
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
|